These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31628935)

  • 1. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
    Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
    J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J; Liu W; Li Y; Li L; Hölscher C
    Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
    Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
    Shi L; Zhang Z; Li L; Hölscher C
    Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
    Duffy AM; Hölscher C
    Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.
    Han L; Hölscher C; Xue GF; Li G; Li D
    Neuroreport; 2016 Jan; 27(1):23-32. PubMed ID: 26555034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
    Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury.
    Bai B; Li D; Xue G; Feng P; Wang M; Han Y; Wang Y; Hölscher C
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):333-343. PubMed ID: 33500109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
    Jalewa J; Sharma MK; Hölscher C
    J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
    Jiao JJ; Hölscher C; Li T; Dong XF; Qu XS; Cao Y; Wu MN; Wang ZJ; Qi JS
    Sheng Li Xue Bao; 2017 Apr; 69(2):135-145. PubMed ID: 28435972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
    Panagaki T; Gengler S; Hölscher C
    J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO; Li Y; Glotfelty EJ; Tweedie D; Greig NH
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.